Skip to main content

Table 6 A summary of GRPR targeted radiopharmaceuticals and their serum stabilities, tumour-to-blood (T:B) and tumour-to-muscle (T:M) ratios at a given time point post-injection

From: The aluminium-[18F]fluoride revolution: simple radiochemistry with a big impact for radiolabelled biomolecules

[18F]AlF radioconjugate Serum stability at 1 h (%)a T:B ratio T:M ratio Time point p.i. (h)b References
[18F]AlF-NODAGA-RM1 > 90 10.29 14.58 2 Liu et al. (2013)
[18F]AlF-NODAGA-AMBA 72.5 8c 2 Liu et al. (2013)
[18F]AlF-NOTA-8-Aoc-BBN(7–14)NH2 49.51 1 Dijkgraaf et al. (2012)
[18F]AlF-NOTA-4,7-lanthionine-BBN > 80 (human serum) 0.71 9.11 2 Carlucci et al. (2015)
[18F]AlF-NOTA-2,6-lanthionine-BBN > 80 (human serum) 1.24 6.7 2 Carlucci et al. (2015)
[18F]AlF-NOTA(6)-MATBBN > 95 (human serum) 9.44 30.70 1 Pan et al. (2014)
[18F]AlF-JMV5132 106 305c 1 Chatalic et al. (2014)
[18F]AlF-NOTA-P2-RM26 > 98 87 159 3 Varasteh et al. (2013)
  1. aIntact parent radioconjugate in mouse serum after 1 h incubation, unless stated otherwise
  2. bThe timepoint post-injection where T:B and T:M data is reported. T:B = tumour-to-blood ratio and T:M = tumour-to-muscle ratio calculated from ex vivo biodistribution data presented in the original manuscript and represented as a mean value
  3. cEstimated from graphical data in the original manuscript